Merck is discontinuing development of MK-7710 (formerly known as CD24Fc), a Phase III Covid-19 therapeutic asset acquired from OncoImmune during November 2020.

The U.S. Food and Drug Administration issued a Complete Response Letter (CRL) to Merck for the company’s supplemental Biologics License Application for Keytruda (pembrolizumab) in high-risk early-stage triple-negative breast cancer.

Amathus Therapeutics, a biopharmaceutical company working on small molecule modulators across diverse genetically defined diseases, entered into a strategic collaboration with Merck to develop novel small molecule treatment candidates for neurodegenerative diseases.

The United States plans to double the country’s order of the single-shot Johnson & Johnson coronavirus vaccine, procuring an additional 100 million doses, a White House official said on March 10.

U.S. drugmaker Merck & Co. Inc. said on March 6 the experimental antiviral drug molnupiravir the company is developing with Ridgeback Bio showed a quicker reduction in infectious virus in its phase 2a study among participants with early Covid-19.

The United States will have enough Covid-19 vaccine for every American adult by the end of May, President Joe Biden said on March 2 after Merck & Co. agreed to make rival Johnson & Johnson’s inoculation.

Merck entered into multiple agreements to support efforts to expand manufacturing capacity and supply of SARS-CoV-2/Covid-19 medicines and vaccines.

Merck & Co. will help make rival Johnson & Johnson’s Covid-19 vaccine in order to boost the slower-than-promised production of the one-dose shot, U.S. President Joe Biden said on March 2.

Merck will have to wait to see if a Covid-19 therapeutic gained in November through the $425 million acquisition of OncoImmune can receive Emergency Use Authorization (EUA) after the U.S. Food and Drug Administration requested additional data beyond the Phase III study announced during 2020

For the second year in a row, California-based Agilent Technologies – a leader in diagnostics and applied chemical markets – was ranked as one of Barron’s most sustainable companies.